Luis Rivera Colon, MD
Internal Medicine · Rio Piedras, PRNPI 1376608984
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,971 of the $20,775 with a category attached, or 72.1%. It is spread thinly across 24 manufacturers, the largest accounting for just 22.6%. Reporting peaked in 2019 at $6,038 and has fallen 70.5% since, to $1,779 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 527 payments — averaging $39.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Merck$5K
- Sanofi-aventis U.S. LLC$3K
- Boehringer Ingelheim$2K
- Novo Nordisk$1K
- Johnson & Johnson$976
- plus $5K from 18 others
Across 68 payments — averaging $8776.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$476K
- Novo Nordisk AS$99K
- Eli Lilly$22K
What the payments were for
- Consulting fees$5,45826%
- Speaking & faculty fees$2001%
- Travel & lodging$1311%
- Food & beverage$14,97172%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 151 | $4,688 |
| Merck | 30 | $4,673 |
| Sanofi-aventis U.S. LLC | 44 | $2,771 |
| Boehringer Ingelheim | 55 | $1,674 |
| Novo Nordisk | 37 | $1,286 |
| Johnson & Johnson | 34 | $976 |
| Lilly USA, LLC | 14 | $957 |
| PBG Puerto Rico LLC | 43 | $864 |
| Eli Lilly Export S.A. Puerto Rico Branch | 28 | $615 |
| Dexcom, Inc. | 12 | $330 |
| Eli Lilly | 17 | $292 |
| Abbott | 14 | $269 |
| GSK | 8 | $247 |
| Bayer Puerto Rico Inc. | 8 | $169 |
| Bayer | 2 | $168 |
| Pfizer Pharmaceuticals LLC | 4 | $140 |
| E.r. Squibb & Sons, L.L.C. | 7 | $133 |
| Amgen | 1 | $119 |
| AbbVie | 5 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $112 |
| Pfizer | 4 | $75 |
| Exact Sciences | 2 | $50 |
| Boston Scientific | 1 | $36 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$2,450
- DISEASE STATE$1,508
- GARDASIL9$1,500
- FARXIGA$1,048
- BREZTRI$613
- JARDIANCE$476
- MOUNJARO$353
- Ozempic$332
- XARELTO$250
- AIRSUPRA$244
- ZEPBOUND$237
- RYBELSUS$237
- SOTAGLIFLOZIN$200
- CAPVAXIVE$120
- Repatha$119
- LOKELMA$119
- SOLIQUA 100/33$104
- TZIELD$104
- TOUJEO$104
- DEXCOM G7 GSS (161)$102
How this compares
$20,775 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 329 | $246,196 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 278 | $220,762 |
| JardianceEmpagliflozin | 178 | $149,170 |
| Xigduo XrDapaglifloz Propaned/Metformin | 176 | $133,468 |
| TrulicityDulaglutide | 97 | $105,787 |
| GlyxambiEmpagliflozin/Linagliptin | 112 | $94,422 |
| OzempicSemaglutide | 94 | $93,306 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 98 | $67,018 |
| EliquisApixaban | 78 | $48,720 |
| SynthroidLevothyroxine Sodium | 555 | $44,616 |
| XareltoRivaroxaban | 48 | $41,180 |
| SynjardyEmpagliflozin/Metformin Hcl | 53 | $33,464 |
| MounjaroTirzepatide | 20 | $21,460 |
| LantusInsulin Glargine,hum.Rec.Anlog | 204 | $20,899 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 196 | $19,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jardiance, Glyxambi, Synjardy Xr, Synjardy | $1,674 | $576,476741 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $4,688 | $254,370354 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N | $957 | $145,244295 claims |
| Novo NordiskOzempic | $1,286 | $93,30694 claims |
| PfizerEliquis | $75 | $48,72078 claims |
| AbbVieSynthroid | $114 | $44,616555 claims |
| Johnson & JohnsonXarelto | $976 | $41,18048 claims |
| Sanofi-aventis U.S. LLCLantus | $2,771 | $20,899204 claims |
| MerckJanuvia | $4,673 | $19,09718 claims |
| GSKBreo Ellipta | $247 | $5,79314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Rio Piedras
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Ronald Collazo PaganManati$206K
- Angel VinuelaDorado$182K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.